Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 12 citing articles:

Clinico-pathological factors predicting pathological response in early triple-negative breast cancer
Clara Helal, Lounes Djerroudi, Toulsie Ramtohul, et al.
npj Breast Cancer (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Serum Enzymes and Pathologic Complete Response to the Addition of Targeted Therapy in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer Patients
Zongshun Chen, Jing Zhang, Wei Chen, et al.
Annals of Surgical Oncology (2025)
Closed Access | Times Cited: 1
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer
Marleen Kok, Robbert-Jan Gielen, Sylvia Adams, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 30, pp. 3523-3529
Closed Access | Times Cited: 7
Pembrolizumab

Reactions Weekly (2025) Vol. 2046, Iss. 1, pp. 345-345
Closed Access
Different activity and toxicity of immunotherapy in monozygotic twins diagnosed with early triple-negative breast cancer: a case report
Marta Perachino, Lucia Del Mastro, Giulia Buzzatti, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer
Alejandro Ríos-Hoyo, Jiawei Dai, Tony Noël, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104494-104494
Closed Access
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study
Matheus de Oliveira Andrade, Isabella Gonçalves Gutierres, Monique Celeste Tavares, et al.
The Breast (2025), pp. 104473-104473
Open Access
Detrimental impact of chemotherapy dose reduction or discontinuation in early stage triple-negative breast cancer treated with pembrolizumab and neoadjuvant chemotherapy: A multi-center experience
Jayasree Krishnan, Archit Patel, Arya Mariam Roy, et al.
Clinical Breast Cancer (2024) Vol. 24, Iss. 8, pp. e701-e711.e2
Closed Access | Times Cited: 3
Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer
Layal Rached, F. Peyre-Pradat, Martina Spotti, et al.
ESMO Real World Data and Digital Oncology (2024) Vol. 5, pp. 100061-100061
Open Access | Times Cited: 2
Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab
Athira Jayan, Jasmine Sukumar, Benjamin David Fangman, et al.
JCO Oncology Practice (2024)
Closed Access | Times Cited: 1
Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer
Casey Connors, Stephanie A. Valente, Ayat ElSherif, et al.
Annals of Surgical Oncology (2024)
Closed Access | Times Cited: 1
Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy
Yoichi Hamai, Yuta Ibuki, Tomoaki Kurokawa, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3529-3529
Open Access
Page 1

Scroll to top